Recently, CHD1L has also been reported as a novel biomarker for patients’ prognosis in several types of malignant tumors including breast cancer12, gastric cancer13, colorectal cancer14, bladder cancer15 as well as ovarian cancer16. This evidence concerns the gene CHD1L and cancer.